SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital Inc. is trending as investors digest news of a new CFO appointment and ongoing management updates, while the community remains divided between bullish sentiment regarding the company's long-term potential in the data center power sector and skepticism over delayed tenant announcements and execution timelines. Investors are actively debating the significance of the new executive hire, potential hyperscaler partnerships, and the speculative nature of the firm's progress in the Permian Basin.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is surging toward new all-time highs as investors capitalize on massive AI-driven demand for HBM4 memory chips, bolstered by a fresh Taiwan facility expansion and multiple analyst price target hikes. The community remains heavily focused on the upcoming earnings report, with widespread debate over whether the stock is primed for a post-earnings breakout to record levels or if the current rally has become too crowded.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to significant regulatory milestones, including the approval of a Nuclear Safety Design Agreement for its Aurora powerhouse and a new materials license for its Atomic Alchemy subsidiary. While the stock continues to face volatility amid its pre-revenue status and recent insider selling, the community is actively debating the long-term potential of its small modular reactor technology in meeting the massive energy demands of AI data centers.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is under intense market scrutiny as investors grapple with cooling North American sales, leadership uncertainty surrounding a prolonged CEO search, and public criticism from founder Chip Wilson. Community discussions remain highly divided, with bulls pointing to the company's strong international growth and stock buyback programs while bears highlight rising competitive pressure from brands like Alo and Vuori.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is trending following a volatile NASDAQ IPO that has seen massive intraday gains, driven by intense investor interest in its AI-driven drone autonomy software and its combat-tested history in Ukraine. The community is heavily focused on the company's low float and the potential for a continued, multi-day short squeeze, with many debating whether the stock represents a long-term defense-tech play or a speculative, high-volatility momentum trade.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is currently a focal point for investors debating the stock's future, as the company faces intensified competition from AI-driven tools while simultaneously leveraging strategic partnerships and share buybacks. Community sentiment remains polarized between those identifying a potential value-based rebound driven by institutional accumulation and those who fear the firm's business model is increasingly vulnerable to technological disruption.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending as the community highlights recent clinical trial progress, including a significant reduction in breast cancer recurrence rates within the open-label arm of the FLAMINGO-01 trial. Investors are actively discussing the upcoming publication of abstract titles for the AACR annual meeting, with many viewing the involvement of the full Steering Committee as a strong signal of scientific credibility and potential institutional backing.

Tectonic is a decentralised non-custodial algorithmic-based money market protocol that allows users to participate as liquidity suppliers or borrowers. Suppliers provide liquidity to the market to earn a passive income, while borrowers are able to borrow liquidity in an over-collateralized fashion.

Tectonic

Tectonic is seeing renewed community interest and positive price momentum, with holders closely monitoring the broader rally across the Cronos ecosystem and holding out hope that the asset can shed several zeros as long-term vaults begin to unlock. While some investors remain skeptical after years of consolidation, many are actively accumulating tokens, citing the potential for parabolic gains if the project gains wider exchange listings or initiates a token burn.

Bob’s Discount Furniture, Inc. is a holding company, which engages in the retail of home furnishings. The firm's products include reclining sofa, table lamp, storage ottoman, top coffee and end table set, rug, storage television stand, and swivel chair. Its store locations include New England, New York, Mid Atlantic, Midwest, and West. The company was founded by Robert Kaufman in 1991 and is headquartered in Manchester, CT.

Bob`s Discount Furniture Inc.

Bob's Discount Furniture is trending as investors debate its valuation and growth potential following recent earnings results and its transition into the public markets. Community discussion is sharply divided between those optimistic about the company's discount business model and omnichannel strategy and skeptics raising concerns over insider selling, tariff risks, and competitive pressure in the furniture sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing a surge in investor interest and trading volume ahead of its upcoming earnings call, with the community actively speculating about a potential buyout and the company's ability to reach critical valuation targets. Investors are closely monitoring the stock's momentum, with ongoing discussions centered on Briumvi's market performance, upcoming sub-Q clinical data, and the potential for a performance-based bonus for management to act as a catalyst for a strategic move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurogene (NGNE) Expected to Announce Quarterly Earnings on Monday

Neurogene (NASDAQ:NGNE) will be releasing its Q4 2025 earnings before the market opens on Monday, March 23. (View Earnings Report at...

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company...

Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Moderate Buy" by Analysts

Neurogene Inc. (NASDAQ:NGNE - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports...

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the...

Neurogene (NASDAQ:NGNE) Now Covered by Canaccord Genuity Group

Canaccord Genuity Group initiated coverage on shares of Neurogene in a research note on Friday. They issued a "buy" rating and a $200.00 price target on the stock...

Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy

Neurogene stock jumps after FDA grants Breakthrough Therapy status to NGN-401 for Rett syndrome treatment.read more...

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did NGNE Stock Surge 25% In Pre-Market Today?

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target 

Equity

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S...

Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit

Neurogene (NASDAQ:NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine...

Neurogene to Participate in Upcoming Investor Conferences

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.24	--	--	N/A
Q3 '25	-$1.25	-$0.99	20.76%	BEAT
Q2 '25	-$1.16	-$1.05	9.47%	BEAT
Q1 '25	-$1.05	-$1.08	-2.86%	MISSED
Q4 '24	-$1.14	-$1.00	12.64%	BEAT

NGNE
Neurogene Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NGNE News

NGNENeurogene Inc